Nature

Analysis of phase II and phase III clinical trial terminations from 2013 to 2023

Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Discov. 23, 656–657; 2024). With ...
ascopubs.org

A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.

Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis. A randomized phase 2 ...
ascopubs.org

Final results of a phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC).

AMIGO: A phase 2 trial of amivantamab in EGFR or MET-amplified gastroesophageal adenocarcinoma (GEA). This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers Symposium. This ...